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Abstract
Background: Intrahepatic cholestasis of pregnancy (ICP) has important fetal implications. There is increased risk for poor
fetal outcomes, including preterm delivery, meconium staining of amniotic fluid, respiratory distress, fetal distress and
demise.
Methods: One hundred and one women diagnosed with ICP between January 2005 and March 2009 at San Francisco
General Hospital were included in this study. Single predictor logistic regression models were used to assess the
associations of maternal clinical and biochemical predictors with fetal complications. Clinical predictors analyzed included
age, race/ethnicity, gravidity, parity, history of liver or biliary disease, history of ICP in previous pregnancies, and induction.
Biochemical predictors analyzed included serum aspartate aminotransferase, alanine aminotransferase, alkaline
phosphatase, total bilirubin, direct bilirubin, albumin, total protein, and total bile acids (TBA).
Results: The prevalence of ICP was 1.9%. Most were Latina (90%). Labor was induced in the majority (87%) and most were
delivered by normal spontaneous vaginal delivery (84%). Fetal complications occurred in 33% of the deliveries, with
respiratory distress accounting for the majority of complications. There were no statistically significant clinical or
biochemical predictors associated with an increased risk of fetal complications. Elevated TBA had little association with fetal
complications until reaching greater than 100 mmoL/L, with 3 out of 5 having reported complications. ICP in previous
pregnancies was associated with decreased risk of fetal complications (OR 0.21, p=0.046). There were no cases of late term
fetal demise.
Conclusions: Maternal clinical and laboratory features, including elevated TBA, did not appear to be substantial predictors
of fetal complications in ICP.
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Introduction
Intrahepatic cholestasis of pregnancy (ICP) is the most common
liver disease seen in pregnancy. It is typically a reversible
cholestatic disease presenting in the second to third trimester of
pregnancy and is characterized by pruritus predominantly of
the palms and soles, elevated serum aminotransferases and/
or elevated serum bile acid levels (.or=10micromol/L) with
spontaneous relief of laboratory abnormalities and symptoms
promptly after delivery but no later than one month post partum.
The incidence of ICP has been found to be variable, with 0.1–
1.5% of the population of Central and Western Europe and North
America, and 1.5–4% in Chile and Bolivia [1]. There is minimal
data on the incidence of ICP in the United States, with recent
reports stating an incidence of 0.3%, and a recent study on a
Latina population in Southern California that determined the
overall prevalence in their population to be 5.6%, 10 to 100 times
higher than previously reported for the U.S. population [2–4]. It is
possible that the low incidence and prevalence rates in the United
States may be due to underdiagnosis.
The pathogenesis of ICP, although not well defined, is thought
to be multifactorial, including an environmental, genetic and
hormonal basis for disease [5]. ICP is relatively benign to women,
but it has been reported to have important fetal implications. ICP
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delivery, meconium staining of amniotic fluid, fetal bradycardia,
fetal distress and fetal demise [2,5,6]. The underlying mechanisms
associated with poor fetal outcome are largely unknown. Poor fetal
outcomes, including asphyxial events and spontaneous preterm
delivery, have been shown to be associated with elevated maternal
total serum bile acids (.40 micromol/L) in pregnancy [7];
however, specific predictors of pregnancy outcomes have not
been consistently identified [6,7]. Maternal treatment with
ursodeoxycholic acid (UDCA), which provides symptomatic relief
of pruritus, has been shown to yield a significant improvement on
biochemical markers, and gestational age of delivery in patients
with ICP [8,9]. The use of UDCA may have important
implications in pregnancy outcomes. The aim of our study is to
describe maternal and fetal characteristics associated with ICP in a
cohort of patients in Northern California and to determine if
significant clinical and biochemical predictors of fetal complica-
tions in women diagnosed with ICP exist.
Materials and Methods
Ethics Statement
This retrospective study is included in the approved University of
California San Francisco (UCSF) CHR (Committee on Human
Research).Tonote,theCHRisthenameofUCSF’sIRB.Thestudy
was approved by the CHR. Informed consent was not required as it
was a retrospective study and study subjects were de-identified.
Patient Population
One hundred and one women diagnosed with clinical ICP were
included in this retrospective study. Patients were identified as
having clinical ICP, if they presented to their obstetric provider in
their second or third trimester of pregnancy with clinical symptoms
of pruritus that could not be defined by anyother etiology.Inclusion
criteria for patient selection included: being diagnosed with ICP by
a physician or certified nurse midwife (CNM), having appropriate
documentation in medical records, and development of pruritus
during the second or third trimester of pregnancy. All subjects had
ICD 9 codes consistent with disorders of biliary ducts at the time of
delivery. Exclusion criteria for the study included diagnosis of
chronic liver disease (hepatitis B, hepatitis C, primary biliary
cirrhosis, primary sclerosing cholangitis, symptomatic cholelithiasis,
cholecystitis, Wilson disease, alpha-1-antitrypsin deficiency, cyto-
megalovirus, Epstein-Barr virus, or autoimmune hepatitis) that
could not be differentiated from ICP at the time of delivery, acute
fatty liver of pregnancy (AFLP) and HELLP syndrome (hemolysis,
elevated liver enzymes, low platelets). Six women with hepatitis B or
C were included in the study, as their presenting symptoms were
consistent with ICP, rather than manifestations of infectious
hepatitis. All patients were seen at the San Francisco General
Hospital (SFGH), Department of Obstetrics and Gynecology,
between January 1, 2005 and March 1, 2009.
Measurements
After IRB approval was obtained, all women who had received
a diagnosis of ICP during the study time period were identified.
The subjects’ medical records were abstracted and data on specific
maternal and fetal characteristics was collected on each patient
included in the study. The maternal data collected included
maternal age at time of delivery, race/ethnicity, type of delivery,
history of ICP in previous pregnancy, history of biliary or liver
disease, spontaneous vs. induced labor, induction indications,
gravidity, parity, weight (kg) and height (cm). BMI was calculated
based on pre-pregnancy weight and height. The biochemical
values evaluated included maximum serum aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT), total bilirubin (TB),
direct bilirubin (DB), albumin (ALB), total protein (TP), alkaline
phosphatase (ALP), total bile acids (TBA), cholic acid (cholic),
deoxycholic acid (deoxy) and chenodeoxycholic acid (cheno) levels.
Serum laboratory tests were typically obtained at the time of
presentation, or at the time of delivery, and in cases where more
than one laboratory test was performed, we used the maximum
values measured for AST, ALT, TB, DB, ALP, TBA, cholic,
deoxy and cheno, and the minimum values for ALB, and TP, as
maximum and minimum values of these respective laboratory tests
most likely correlate with hepatic dysfunction if abnormal. Serum
biochemical and bile acid tests were determined using routine
laboratory methods.
The primary outcome measured in this study was a composite
outcome of one or more fetal or neonatal complications. The fetal
complications included fetal distress, major congenital anomalies,
hyperbilirubinemia, meconium staining of amniotic fluid at delivery,
meconium aspiration, pneumonia, respiratory distress and sepsis.
Fetal distress was defined by repetitive severe variable decelerations,
or repetitive late decelerations, or fetal bradycardia of less than 110
beats per minute lasting 3 minutes or longer, requiring emergent
delivery. Respiratory distress was defined as any neonate that
required intubation, continuous positive airway pressure (CPAP),
bag/mask ventilation post-partum, diagnosis of pneumonia, docu-
mentation of respiratory distress secondary to meconium aspiration,
or documentation by a health care provider based on physical exam.
Additional perinatal data collected included estimated gestational
age at time of delivery, birth weight (grams), 1 minute Apgar score
and 5 minute Apgar score. The clinical, biochemical and pregnancy
outcomes were extracted for each patient by review of patient
medical records with a data abstraction form and then entered into
an excel spreadsheet to create the ICP database.
Statistical Analysis
Descriptive statistics were used to characterize the cohort for our
data analysis. The results are expressed as means +/2 SD, or
medians and interquartile ranges, as appropriate. Continuous
predictorvariables were dichotomizedtobinaryvariables forease of
interpretability. Advanced maternal age was defined as age greater
than 35 years at delivery. The maximum values for AST, ALT,
cholic, deoxy, and cheno were dichotomized into binary variables
based on our laboratories standardized normal values. AST was
considered high if values were greater than 40 IU/L, ALT was
considered high if values were greater than 45 IU/L, cholic
was considered high if values were greater than 3.1 mmoL/L, deoxy
was considered high if values were greater than 7.3 mmoL/L, and
cheno was considered high if values were greater than 9.9 mmoL/L.
TBA was then categorized into four groups: less than 10 umoL/L,
10–40 umoL/L,40–100 umoL/L,andgreaterthan100 Iu/L.The
‘less than 10 umoL/L’ was used as the reference group for
comparison. Single-predictor logistic regression models were used
to assess the unadjusted associations of clinical and biochemical
predictors with fetal complications and respiratory distress. Two
predictor models were generated, controlling for a maternal history
of hepatic and biliary disease. Results were expressed as odds ratios.
Statistical analysis was conducted in STATA version 10. (Stata
Corp,College Station,TX).Allreportedp valuesaretwo-sided,and
p,0.05 was considered statistically significant.
Results
ICP was diagnosed in 101/5,238 pregnant women from
January 1, 2005 to March 1, 2009, for a prevalence of 1.9%.
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population. The mean maternal age at time of delivery was 27.5
years (S.D. 65.8) with a range of 16 to 41 years. Most of the ICP
population was Latina (90%), whereas in the overall population
during the study period 63% of pregnant women were Latina.
Delivery methods in women with ICP included normal sponta-
neous vaginal delivery (84%), low transverse cesarean section
(14.9%), and one patient had a vacuum assisted delivery. Delivery
methods in the overall population included normal spontaneous
vaginal delivery (74%), vacuum assisted delivery (3.5%), forceps
delivery (2%) and low transverse cesarean section (21%). A history
of ICP in previous pregnancies existed in 20 of the ICP patients,
and 16 women had a history of other biliary or hepatic disease
(Table 2). Medical histories were significant for cholelithiasis in five
patients, cholecystitis in two patients, cholecystectomy in three
patients, hepatitis A in one patient, hepatitis B in three patients,
and hepatitis C in three patients. It was deemed by documentation
that none of the patients had active disease at the time of
presentation with ICP-associated symptoms. There were also
maternal histories of post-partum hemorrhage, spontaneous
abortion, peri-natal fetal death, and postnatal infant death in
previous pregnancies (Table 2). Most of the patients in the ICP
cohort were induced (87%), with diagnosis of ICP being the
predominant indication (95.5%). Other induction indications
included premature rupture of membranes (PROM), diabetes,
oligohydramnios, and pre-eclampsia. The average pre-pregnancy
BMI was calculated to be 27.7 (S.D. 66.1). All patients presented
with pruritus during the second or third trimester, and no patients
were found to be jaundiced. UDCA was administered to 29% of
the patients for treatment of pruritus.
Table 3 describes the median maximum laboratory values in the
ICP cohort prior to delivery. Total bile acids were measured in
72% of the patients. The median maximum TBA was 23.4, with
an interquartile range of 10.6 to 42. Elevated TBA greater than
10 mmoL/L were present in 75% of the patients that had TBA
sent. Cholic acid, deoxycholic acid and chenodeoxycholic acid
were measured in 72 patients. Hepatitis A serology was assayed in
45 patients; 43 patients had non-reactive titers. Hepatitis B surface
antigen was assayed in 99 patients; 97 patients had non-reactive
titers. Hepatitis B core antibody titers were obtained in 50 patients;
47 patients had non-reactive titers. Hepatitis C antibody titers
were assayed in 55 patients; 52 patients had non-reactive titers.
Neonatal characteristics at the time of delivery are described in
Table 4. Mean estimated gestational age was 37 weeks (S.D. 61.2)
and mean birth weight was 3,126.3 grams (S.D. 6519.1). Mean
one minute and five minute Apgar scores were 8 (S.D. 61) and 9
(S.D. 61). There were no 5 minute Apgar scores less than 7. In
the overall population of pregnant women, 3.8% of deliveries had
a 5 minute Apgar score less than 7. Fetal complications occurred
in 33% of the deliveries in the ICP cohort. The most common
Table 1. Maternal Demographics.
N=101 +/2 S.D.
Age (years) 27.5+/25.8
Race/ethnicity
Latina 91
Asian 3
Black 4
White 2
Unknown 1
Delivery Methods
Vaginal 86
Cesarian section 15
History ICP 20
Liver/Biliary History 16
Induction 88
Induction Indications
ICP 84
PROM 1
Diabetes 1
Oligohydramnios 1
Preeclampsia 3
Gravida n=98 3+/21.4
Parity n=98 1+/21.2
BMI n=76 27.7+/26.1
S.D.=standard deviation, BMI=body mass index.
doi:10.1371/journal.pone.0028343.t001
Table 2. Maternal Medical History.
N=101
Cholecystitis 2
Cholecystectomy 3
Cholelithiasis 5
Chorioamnionitis 1
Hepatitis A 1
Hepatitis B 3
Hepatitis C 3
Postpartum Hemorrhage 2
Spontaneous Abortion 2
*Perinatal Death 1
*Postnatal Death 1
Perinatal death=stillbirths or death within 1
st week of life.
Postnatal death=death after 1
st week of life.
doi:10.1371/journal.pone.0028343.t002
Table 3. Maternal Laboratory Values*.
N Median Interquartile Range
AST (U/L) 99 44 30–89
ALT (U/L) 99 62 33–139
ALP (U/L) 71 251 192–329
TB (mg/dL) 81 0.5 0.4–0.8
DB (mg/dL) 77 0.2 0.1–0.3
ALB (g/dL) 73 3.5 3.4–3.7
TP (g/dL) 74 6.5 6.0–6.7
TBA (mmol/L) 73 23.4 10.6–42
Cholic (mmol/L) 72 12 3.8–25.0
Deoxy (mmol/L) 72 2.5 1.7–4.3
Cheno (mmol/L) 72 6.1 3.0–13.9
*based on maximum value recorded.
U=units, L=liter, mg=milligram, dL=deciliter, mmol=micromole.
doi:10.1371/journal.pone.0028343.t003
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staining of the amniotic fluid, and fetal distress. Fetal demise did
not occur in any of the patients. Fetal complication occurred in 5
out of 18 patients in the TBA ,10 group (28%), 10 out of 34
patients in the TBA 10–40 group (29%), 3 out of 16 in the TBA 40–
100 group (19%) and 3 out of 5 in the TBA .100 group (60%).
Predictors of fetal complications were evaluated by logistic
regression and described in Table 5. Advanced maternal age may
have a minor impact on risk, but the uncertainty around this is
very wide. Latina race appeared to have a substantial protective
effect, but uncertainty around this result was again very great and
it did not reach statistical significance. Maternal history of hepatic
or biliary disease not including ICP, although not statistically
significant, appeared to be associated with higher risk of fetal
complications (OR 2.10, 95% CI 0.70, 6.28). A maternal history of
having ICP in a previous pregnancy was found to be associated
with an 80% decreased odds of having a fetal complication in the
current pregnancy (OR 0.21, p=0.046). Elevated maternal
laboratory values (AST, ALT) during pregnancy did not correlate
substantially with increased odds of fetal complications. TBA.
10 mmol/L were not found to be statistically significant predictors
of fetal complications. This study suggests that TBA.100 may
indicate substantially increased risk, but the confidence interval is
too wide to provide strong evidence for this. The use of ursodiol to
treat pruritus during pregnancy was not associated with a
decreased risk of fetal complications (OR 1.34, p=0.53). Twenty
nine patients were treated with UDCA. The median TBA for
those who received UDCA was 23.4 (interquartile range 12.8 to
31.7) and the median TBA for those who did not receive UDCA
was 21.9 (interquartile range 8.3 to 42); this difference was not
statistically significant (p=0.57, Mann-Whitney test). Four out of
five patients with TBA.100 were treated with ursodiol. Those
patients who were induced may have an increased risk of fetal
complications (OR 2.57, p=0.24). The number of previous
pregnancies and previous births were not statistically significant
predictors of fetal complications; however, it does appear that
there is a trend towards reduced risk with higher values (gravidity
OR 0.77, p=0.15; parity 0.74, p=0.16). No qualitative dif-
ferences were found when controlling for maternal history of
hepatic or biliary disease in a two predictor models.
Discussion
The data on ICP in the United States is extremely limited
despite its high frequency. The prevalence of ICP in this
retrospective cohort of patients was found to be 1.9%, similar to
other data from Central and Western Europe. Previous literature
reports 0.3% prevalence in the United States [4]. The prevalence
is higher in Chile and Bolivia, with rates of 1.5–4%, and 9%
[1,10]. In our study, in which women with ICP were identified
from an ethnically/racially mixed study population, Latina women
had a greater likelihood of having ICP than other women (RR
4.96, 95%CI 2.59, 9.51, p,0.0001), suggesting that genetic factors
may play a role in the development of ICP. In a recent study of a
largely Latina Los Angeles population, the overall prevalence of
ICP was found to be 5.6% [3].
Although ICP is usually relatively benign to the mother, it is
known that the risk of fetal complications is increased in
pregnancies affected by ICP. These include increased risks of
meconium stained amniotic fluid, preterm delivery, fetal distress
and intrauterine fetal demise (IUFD). In this study, we found that
33% of the births had an associated perinatal complication
including respiratory distress syndrome, meconium staining of
amniotic fluid, fetal distress, congenital anomalies, sepsis, hyper-
bilirubinemia and pneumonia. There were no episodes of IUFD.
Previous studies have reported meconium staining in 24%, and
intrauterine fetal demise in 0.4% of ICP cohorts [7]. The
incidence of meconium staining of amniotic fluid at full term in
a normal pregnant population varies between 17–24% and at 37
weeks gestational age is ,5%, compared to the 9% incidence
observed in our study [11,12]. Respiratory distress accounted for
52% of the complications observed post-partum.
It has been reported that the incidence of respiratory distress
syndrome in neonates born to mothers with ICP is twice that of the
normal population [13,14]. This can be due in part to the earlier
gestational age at delivery, but neonatal respiratory distress syn-
drome has been demonstrated to be associated with ICP, based on
analysis of bronchoalveolar lavage fluid of neonates born to mothers
with ICP [14]. Specifically, it has been hypothesized that bile acids
can produce surfactant depletion in the alveoli [13,14]. Animal
models have shown microscopic findings of atelectasis, poling of
eosinophilic substances in intra-alveolar spaces, and formation of
Table 4. Fetal Characteristics at Birth.
N=101 +/2 S.D.
EGA (weeks) 37+/21.2
Birthweight (grams) 3126.3+/2519.1
1 minute APGAR 8+/21
5 minute APGAR 9+/21
Complications 33
Respiratory Distress 17
Meconium 9
Fetal Distress 5
Congenital Anomalies 2
Hyperbilirubinemia 2
Sepsis 2
Pneumonia 1
S.D.=standard deviation.
doi:10.1371/journal.pone.0028343.t004
Table 5. Predictors of Fetal Complications.
OR P 95% CI
Advanced Maternal Age 1.20 0.80 0.28–5.17
Latina 0.38 0.15 0.10–1.42
Historyliver/biliary disease 2.10 0.19 0.70–6.28
ICP in previous pregnancy 0.21 0.05 0.05–0.97
Elevated ALT 0.82 0.66 0.34–1.97
Elevated AST 0.76 0.53 0.32–1.80
TBA (reference group ,10)
TBA 10–40 1.08 0.90 0.30–3.85
TBA 40–100 0.60 0.54 0.12–3.05
TBA.100 3.90 0.20 0.49–30.76
Ursodiol use 1.34 0.53 0.53–3.38
Gravida 0.77 0.15 0.54–1.10
Parity 0.74 0.16 0.49–1.13
Induction 2.57 0.24 0.53–12.36
doi:10.1371/journal.pone.0028343.t005
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cholic acid [15]. When treated with surfactant, alveoli responded
appropriately, and had increased aeration [15]. In another study,
bronchial alveolar lavage was performed during necropsy on 12
infants and it was found that there were lower phospholipid levels,
and higher bile acid levels [16]. This suggests a possible interaction
between bile acids and surfactant mediated through the phospho-
lipase A2, which synthesizes surfactant in the lung [16]. More details
are necessary to determine the effects of bile acids on fetal lung
maturity, surfactant production, and respiratory distress.
The risk of fetal morbidity and mortality in ICP is higher than
in the general population [7,17–20]. Even though in this study
there were no cases of IUFD, the overall complication rate is still
concerning. Current management of ICP is induction of labor at
36–38 weeks gestational age, regardless of TBA levels; however, it
has been suggested that expectant management can be considered
for those with TBA,40 mmol/L [7]. A study by Glantz et al
concluded that pregnancies in women with TBA.40 mmol/L had
an increased fetal risk of preterm delivery, asphyxia events,
meconium staining of amniotic fluid, and green-staining of
placenta and membranes, while those with TBA between 10–
39 mmol/L had minimal to no increased risk compared to women
with pruritus but normal TBA, and that based on these findings
the latter women could be managed expectantly, and possibly
reduce the costs of medical care. [7] It did not, however, provide
the odds ratios for these direct comparisons, so the comparability
of their results to ours is unclear. In our study, there were no
statistically significant clinical or biochemical predictors associated
with an increased risk of fetal complications. This may be in part
due to differences in clinical practice, where we typically deliver
patients with identified ICP at ,37 weeks gestational age, where
as in the Glantz et al. study there were no specific instructions
given to obstetricians on how to manage the pregnancies or timing
of delivery. This may also explain the differences seen in fetal
demise, as the majority of cases of IUFD occur late in gestation,
usually after 36 weeks of gestation. In our study, only prior history
of ICP showed significance, and this was an association with a
decreased rate of fetal complication. A history of hepatic/biliary
disease, although not statistically significant, may have an
important association with increased fetal complications. Those
with hepatic or biliary disease may be at increased risk for fetal
complications. A maternal history of ICP in a previous pregnancy
was estimated to decrease the risk of complication by 80%,
suggesting an increase in awareness of ICP in the patient and
provider, with possibly increased fetal monitoring, and earlier
maternal obstetric care, which can decrease the chance of fetal
complications. The mean gestational age in those with a history of
ICP was 37 weeks (range 36–39), and the mean gestational age in
those that did not have ICP in previous pregnancies was also 37
weeks (range 33–40). The proportion of deliveries with a
gestational age greater than 37 weeks was 35% in those with a
history of ICP and 26% in those without a history of ICP.
Current pharmacologic treatment includes the use of UDCA
upon diagnosis of ICP. UDCA has been shown to have greater
efficacy than other treatment modalities, including the use of
S-adenosyl-L-methionine, dexamethasone, and cholestyramine,
regarding maternal pruritus, and improving TBA and serum
transaminases. In a randomized, double-blinded placebo con-
trolled trial by Glantz et al., it was found that UDCA was more
effective than dexamethasone in relieving pruritus, and improving
serum biochemical markers of ICP, however there was no effect of
UDCA or dexamethasone on fetal complication rates. [21] In our
study, there was no clinically significant effect of UDCA on fetal
complications (Table 5).
TBA was categorized into four separate groups: normal or less than
10 mmol/L, 10–40 mmol/L, 40–100 mmol/L, and .100 mmol/L.
When compared to the reference group of normal (,10), there was no
increase in fetal complications in the TBA 10–40 group or TBA 40–
100 group, suggesting that elevated TBA up to 100 may not be
particularly useful in determining the risk of fetal complications. When
TBA was greater than 100 mmoL/L, 60% had reported complica-
tions, for an OR 3.90 but with a wide confidence interval (95% CI
0.49, 30.76).
Our study had several limitations. In a retrospective study, it is
difficult to control for missing data and uniformity of laboratory
studies ordered within a cohort. The majority of the patients did
have TBA, AST, and ALT sent. However, not all women were
tested for other causes of potential liver disease. Total serum bile
acids typically peak 30–90 minutes after meals, and there was no
documentation of whether the TBA levels sent were fasting levels.
Most likely, they were sent as part of routine laboratory testing
done at the time of the clinic visit, or when the patient was
admitted for delivery. The criteria for diagnosing ICP are also
subjective, as there are no current uniform criteria for the
diagnosis of ICP. Most studies use elevated serum bile acids or
serum transaminase levels combined with pruritus during
pregnancy; however, the serum bile acids may not necessarily be
elevated at the time of a blood draw due to fasting versus non
fasting state and there may be a greater rise towards the later
weeks of pregnancy. In addition, the turnaround time for receiving
the laboratory results may be 1–2 weeks, making it difficult to
await the result when deciding on induction of labor to reduce
potential fetal complications, specifically fetal demise.
In summary, in this cohort of ICP patients, 33% of the
pregnancies resulted in perinatal complications, with respiratory
distress being the most common complication. A history of liver
and biliary disease and TBA greater than 100 may be clinically
relevant, but our data were not conclusive. Our results suggest that
it may be difficult to use maternal clinical and biochemical features
to accurately predict fetal complications.
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